For central nervous system (CNS) applications, attempts are being made to deliver AAV gene therapy directly to the brain parenchyma or the cerebrospinal fluid (CSF) space by intra-cisterna magna ...

When Robert Atchison and his colleagues at the University of Pittsburgh first stumbled across adeno-associated viruses (AAV) in 1965, they initially supposed they were merely defective byproducts ...